Home » Articles » Angelini Pharma – An overview of the US pharma landscape
Vol. 40 | Vol. 40(5) - September / October 2022 | ADVERTORIAL

Angelini Pharma – An overview of the US pharma landscape

by
Angelini Pharma

BACKGROUND
Over the past 10+ years the pharmaceutical Industry has utilized CDMO’s at an increasing level from year to year never seen prior to this period. The reasons are multidimensional involving a combination of new complex molecules for drug therapies such as NASH, antivirals (e.g. Hepatitis and most recently CoVID) as well as the ever expanding Oncology sector, all with small molecules being still dominant.

You may also like

MAGAZINE Vol. 40 | Vol. 40(5) - September / October 2022 | COLUMN: API of the Month

Mavacamten

by R. Souza • October 3, 2022

Latest issue

Vol. 44(4) – July / August 2026

View Issue
    

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

“Contents from Magazine” offers curated articles and insights from the field of chemistry, focused on research, data, and scientific developments

View all content

Most popular

Trusted by

angelini
ajinomoto
almac
asymchem
bachem
curia
deimos
dorra
evonik
faggi
faravelli
gryos
ibsa
indena
jiuzhou
JMP
lonza
olon
procos
PHT
sinocompound
SK_pharmteco
STA-Wuxi
stevanato
thermo
valsy
veranova
YMC

40 years connecting the world of science for industry

Our journals:

@2026 - All Right Reserved - P.IVA 06817720151

Login